IDENTIFIKASI KEBANGKRUTAN DI PERUSAHAAN FARMASI : MODEL ALTMAN Z-SCORE ANALYSIS (STUDI PADA PERUSAHAAN FARMASI YANG TERDAFTAR DI BURSA EFEK INDONESIA PERIODE 2012-2016)
DOI:
https://doi.org/10.29303/jmm.v7i4.342Abstract
Every company has different problems of each type, including in the categorization of whether the company is categorized to be bankrupt or not. This study was conducted to study and detect the possibility of bankruptcy of pharmaceutical companies in Indonesia using the Altman Z-Score model. The sample used in this study is a pharmaceutical company listed on the Indonesia Stock Exchange (BEI) and the company publishes regular financial statements in 2012 until 2016. In the Altman Z-Score model, grouping companies into three categories ie not bankrupt, prone to bankruptcy, and bankruptcy. For companies that fall into the category of bankruptcy, should be more careful in asset management and corporate policy making and strive to continue to improve the company's performance and try to utilize assets owned more effectively and efficiently, so that will gain a more optimal advantage. While for companies that are in a healthy condition must still maintain and improve the performance of the company, so it will be sustinable and minimize the occurrence of bankruptcy. Setiap perusahaan memiliki permasalahan yang berbeda dari setiap jenisnya, termasuk dalam pengkategorian apakah perusahaan tersebut dikatakan bangkrut ataukah tidak. Penelitian ini dilakukan untuk mempelajari dan mendeteksi kemungkinan terjadinya kebangkrutan perusahaan farmasi yang ada di Indonesia dengan menggunakan hitungan model Altman Z-Score. Sampel yang digunakan dalam penelitian ini adalah perusahaan farmasi yang terdaftar di Bursa Efek Indonesia (BEI) dan perusahaan tersebut menerbitkan laporan keuangan secara teratur pada tahun 2012 sampai dengan tahun 2016. Dalam model Altman Z-Score, mengelompokkan perusahaan menjadi tiga kategori yaitu tidak bangkrut, rawan bangkrut, dan bangkrut. Bagi perusahaan yang termasuk dalam kategori rawan bangkrut, harus lebih berhati–hati dalam pengelolaan aset dan melakukan pengambilan kebijakan perusahaan serta berusaha untuk terus meningkatkan kinerja perusahaan dan berusaha memanfaatkan aset yang dimilikinya dengan lebih efektif dan efisien, sehingga akan memperoleh keuntungan yang lebih optimal. Sedangkan bagi perusahaan yang berada dalam kondisi sehat harus tetap mempertahankan dan meningkatkan kinerja perusahaannya termasuk melakukan inovasi dan pengembangan bisnisnya, sehingga akan tetap terjaga keberlangsungannya dan memperkecil kemungkinan terjadinya kebangkrutan.Keywords :altman z-score, pharmaceutical company, bankruptcy, sustainableKata kunci : Altman z-score, perusahaan farmasi, kebangkrutan, keberlangsunganDownloads
Published
2018-12-08
How to Cite
Haryanto, T. (2018). IDENTIFIKASI KEBANGKRUTAN DI PERUSAHAAN FARMASI : MODEL ALTMAN Z-SCORE ANALYSIS (STUDI PADA PERUSAHAAN FARMASI YANG TERDAFTAR DI BURSA EFEK INDONESIA PERIODE 2012-2016). Jurnal Magister Manajemen, 7(4), 1–16. https://doi.org/10.29303/jmm.v7i4.342
Issue
Section
Articles
License
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a CC BY 4.0. This license allows authors to use all articles, data sets, graphics, and appendices in data mining applications, search engines, web sites, blogs, and other platforms by providing an appropriate reference. The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in JMM.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).




